The PE Ratio as of September 2024 (TTM) for 4D Molecular Therapeutics, Inc. (FDMT) is -6.79

According to 4D Molecular Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -6.79. This represents a change of -30.53% compared to the average of -9.77 of the last 4 quarters.

4D Molecular Therapeutics, Inc. (FDMT) Historical PE Ratio (quarterly & annually)

How has FDMT PE Ratio performed in the past?

The mean historical PE Ratio of 4D Molecular Therapeutics, Inc. over the last ten years is -24.33. The current -6.79 PE Ratio has changed 2.69% with respect to the historical average. Over the past ten years (40 quarters), FDMT's PE Ratio was at its highest in in the June 2022 quarter at -2.06. The PE Ratio was at its lowest in in the September 2020 quarter at -27.91.

4D Molecular Therapeutics, Inc. (FDMT) PE Ratio by Quarter and Year

Discovering the peaks and valleys of 4D Molecular Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

4D Molecular Therapeutics, Inc. (FDMT) Average PE Ratio

How has FDMT PE Ratio performed in the past?

The current PE Ratio of 4D Molecular Therapeutics, Inc. (FDMT) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

4D Molecular Therapeutics, Inc. (FDMT) PE Ratio vs. Peers

How is FDMT’s PE Ratio compared to its peers?

4D Molecular Therapeutics, Inc.’s PE Ratio is less than TCR2 Therapeutics Inc. (-0.44), greater than Revolution Medicines, Inc. (-13.31), less than Black Diamond Therapeutics, Inc. (-3.70), less than Atreca, Inc. (-0.04), less than Passage Bio, Inc. (-0.57), less than Century Therapeutics, Inc. (-0.91), greater than Edgewise Therapeutics, Inc. (-14.14), less than C4 Therapeutics, Inc. (-3.44), less than Mineralys Therapeutics, Inc. (-4.63), greater than Cullinan Oncology, Inc. (-6.96), less than Biomea Fusion, Inc. (-1.83), greater than Stoke Therapeutics, Inc. (-7.92), greater than Akero Therapeutics, Inc. (-8.95), less than Homology Medicines, Inc. (-0.01), less than Gossamer Bio, Inc. (-2.55), less than Replimune Group, Inc. (-3.26), less than Nuvectis Pharma, Inc. (-4.95), less than Lyra Therapeutics, Inc. (-0.18), less than Kronos Bio, Inc. (-0.58),

Build a custom stock screener for 4D Molecular Therapeutics, Inc. (FDMT) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like 4D Molecular Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

4D Molecular Therapeutics, Inc. (FDMT) and other stocks custom spreadsheet templates

The easiest way to analyze a company like 4D Molecular Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.